Bcr Antibody (G6): sc-104

Bcr Antibody (G6) is a mouse monoclonal IgG1 kappa light chain antibody, specifically raised against a synthetic peptide derived from the amino acid sequence of the human Bcr (Breakpoint Cluster Region) protein. The Bcr protein, also known as Breakpoint Cluster Region protein, is primarily localized in the cytoplasm where it functions as a GTPase-activating protein (GAP) for the Rac1 p21 GTPase, playing a critical role in regulating cytoskeletal organization, cell migration, and proliferation. Located on chromosome 22, the Bcr gene is famously involved in the formation of the Philadelphia chromosome through a translocation with the c-Abl proto-oncogene on chromosome 9, a genetic event present in approximately 90-95% of chronic myelogenous leukemia (CML) cases. This translocation results in the production of Bcr/Abl fusion proteins, specifically p190 and p210, which possess constitutive tyrosine kinase activity that drives the uncontrolled growth of leukemic cells. Understanding the cellular localization and function of Bcr is essential for elucidating the molecular mechanisms underlying CML and for the development of targeted therapies. Bcr mouse monoclonal antibody (G6) effectively detects both Bcr/Abl p190 and p210 fusion proteins in mouse, rat, and human samples and is compatible with a variety of applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin embedded sections (IHCP). Additionally, Bcr (G6) antibody is available in multiple conjugated forms such as agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and various Alexa Fluor® derivatives, providing flexibility for diverse experimental needs.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Bcr Antibody (G6) References:

1. The BCR gene and philadelphia chromosome-positive leukemogenesis.  |  Laurent, E., et al. 2001. Cancer Res. 61: 2343-55. PMID: 11289094
2. Bcr encodes a GTPase-activating protein for p21rac.  |  Diekmann, D., et al. 1991. Nature. 351: 400-2. PMID: 1903516
3. Identification of two normal bcr gene products in the cytoplasm.  |  Dhut, S., et al. 1988. Oncogene. 3: 561-6. PMID: 3078961
4. The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases.  |  Wiedemann, LM., et al. 1988. Blood. 71: 349-55. PMID: 3276362
5. Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity.  |  Stam, K., et al. 1987. Mol Cell Biol. 7: 1955-60. PMID: 3299055
6. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.  |  Stam, K., et al. 1985. N Engl J Med. 313: 1429-33. PMID: 3864009
7. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.  |  Konopka, JB., et al. 1984. Cell. 37: 1035-42. PMID: 6204766
8. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.  |  de Klein, A., et al. 1982. Nature. 300: 765-7. PMID: 6960256
9. Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.  |  Melo, JV., et al. 1995. Leukemia. 9: 734-9. PMID: 7723412

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Bcr Antibody (G6) has 18 citations in a variety of scientific publications.

Primary antibodies like Anti-Bcr Antibody (G6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Bcr Antibody (G6) Specifications

Alternate Product Name: Bcr

Product Clone Name: G6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Bcr

Epitope Species: human

Product Reactivity/Detection: Bcr/Abl p190 and Bcr/Abl p210 fusion proteins

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 18 citations in various scientific publications

Available Conjugates/Forms for Bcr Antibody (G6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred c-Abl antibody is c-Abl Antibody (24-11): sc-23.